Arthneeti
IR

Indoco Remedies

Q3 FY26Pharmaceuticals & Biotechnology

Indoco Remedies Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹226
Market cap₹2.0K Cr
Updated23 Aug 2026
Read4 min read

The short version

OTC business expected to grow by at least 30% next financial year due to increased consumer marketing and brand extensions. OTC business expected to grow by at least 30% next financial year due to increased consumer marketing and brand extensions.

From Indoco Remedies's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • OTC business expected to grow by at least 30% next financial year due to increased consumer marketing and brand extensions. (Page 18)
  • Indian formulation business targeted for double-digit growth, though 15% may be ambitious; new product introductions (6% of top line) and expanded geographic reach expected to support growth. (Page 13)
  • European business expected to grow at over 20% annually over the next few years, potentially reaching INR400-500 crores by FY 28-29. (Page 9)
  • US business showing promise with several new product launches planned; recovery tied to US FDA approval timing. (Page 13)

2 more points from Indoco Remedies's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Indoco Remedies said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No significant capital expenditure (capex) planned in the near term; company aims to control capex going forward.
  • Maintenance capex expected at around INR 35-40 crores per annum, including energy-saving projects to reduce energy costs.
  • Most investments in business and R&D are already made, leading to substantially lower capex needs over the next 2-3 years.

2 more points from Indoco Remedies's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1Accretion Pharmaceuticals Ltd
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Indoco Remedies said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention specific details about the current or expected order book or pending orders for Indoco Remedies Limited. However, some relevant insights related to business outlook and operations include: - Expectation of at least five new product launches in FY '27 from their own portfolio. - Growth in US filings and approvals in the pipeline, indicating potential future orders. - Strong momentum in OTC business with brand extensions and increased advertising, expected to grow by at least 30%. - European business expected to grow at 20%+ over the next few years, aiming for INR400-500 crores revenue by FY '28-'29.

2 more points from Indoco Remedies's call on order book

Pro opens every point from 15K+ earnings calls

Indoco Remedies — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net loss ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Indoco Remedies Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wanbury Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn Ltd (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Ind-Swift Laboratories Ltd (Q3 FY26)

    Q2 FY26 Revenue: ₹152.64 Cr (Total Income: ₹170.50 Cr), with a year-on-year (Y-o-Y) increase of 1.91%. Key investor presentation takeaways from Ind-Swift Labora

  • Caplin Point Laboratories Ltd (Q3 FY26)

    Approximately INR 385 crores has already been spent; the remainder is planned over the next 12 to 18 months. Key concall takeaways from Caplin Point…

Compare:vs Torrent Pharmaceuticals Ltdvs Laurus Labs Ltdvs Cipla Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Indoco Remedies and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Indoco Remedies Q3 FY26 results?

OTC business expected to grow by at least 30% next financial year due to increased consumer marketing and brand extensions. OTC business expected to grow by at least 30% next financial year due to increased consumer marketing and brand extensions.

What is Indoco Remedies share price analysis?

Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.

Is Indoco Remedies planning capital expenditure?

No significant capital expenditure (capex) planned in the near term; company aims to control capex going forward.

Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.